Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model.
Antibody-dependent enhancement of flavivirus infection, which except for dengue virus is without clear proof in vivo, is still under debate. Recently, postexposure immunoglobulin prophylaxis against tick-borne encephalitis virus, a flavivirus, was claimed to possibly have worsened the outcome of infection due to antibody-dependent enhancement. In the present study, antibody-dependent enhancement and pre- or postexposure protection by passive administration of tick-borne encephalitis virus immunoglobulin were evaluated in a mouse model. Preexposure treatment with homologous murine or heterologous human immunoglobulin provided complete protection against lethal challenge with tick-borne encephalitis virus. For postexposure treatment with antibody, the degree of protection correlated with the amount of immunoglobulin administered and was inversely related to the time interval between infection and treatment. Indications of enhancement of infection would have been increased lethality or reduced mean survival time, but neither was observed under the conditions used in our experiments despite the broad range of immunoglobulin and virus challenge doses applied. In contrast to these in vivo results, antibody-dependent enhancement of tick-borne encephalitis virus infection of murine peritoneal macrophages was readily demonstrable in vitro. Thus, antibody-dependent enhancement of viral infection in vitro does not necessarily predict enhancement in vivo.
Kreil
T R
TR
Department of Pediatric and Infectious Immunology, Institute of Immunology, University of Vienna, Austria.
Eibl
M M
MM
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D002522:Chlorocebus aethiops; D004195:Disease Models, Animal; D004669:Encephalitis Viruses, Tick-Borne / Q000276:immunology* / Q000302:isolation & purification; D004675:Encephalitis, Tick-Borne / Q000517:prevention & control* / Q000821:virology; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D014709:Vero Cells; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D016756:Immunoglobulins, Intravenous; D014765:Viral Vaccines